Over a month ago
Upgrade
UBS analyst Kevin…
UBS analyst Kevin Caliendo upgraded Dentsply Sirona to Buy from Neutral with a price target of $47, down from $58, implying 18% upside potential. Following "extensive" channel checks, the analyst believes the concerns coming out of the company's Q1 earnings, including increased inventories, lower margins, COVID and management uncertainty are "explainable and largely transitory." His analysis of Dentsply's current inventory headwind suggests that the issue is "meaningfully less impactful than 2018, yet the stock is down near 2018 multiples." The analyst also expects the company's margins to stabilize and cash flow to improve going forward. Caliendo views Dentsply Sirona's valuation as "compelling" at current share levels.
Show Hide Related Items >> <<
05/18/22 Dentsply Sirona receives notice of filing delinquency from Nasdaq 05/11/22 Moderna CFO Jorge Gomez departs, recently retired David Meline to continue role 05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 06/01/22 UBS Dentsply Sirona upgraded to Buy from Neutral at UBS 05/11/22 Barrington Dentsply Sirona price target lowered to $51 from $53 at Barrington 05/10/22 Piper Sandler Piper trims Dentsply Sirona target, says recovery could be 'long and costly' 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Upgrade
UBS analyst Kevin…
UBS analyst Kevin Caliendo upgraded Dentsply Sirona to Buy from Neutral with a price target of $47, down from $58.
Show Hide Related Items >> <<
05/18/22 Dentsply Sirona receives notice of filing delinquency from Nasdaq 05/11/22 Moderna CFO Jorge Gomez departs, recently retired David Meline to continue role 05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/11/22 Barrington Dentsply Sirona price target lowered to $51 from $53 at Barrington 05/10/22 Piper Sandler Piper trims Dentsply Sirona target, says recovery could be 'long and costly' 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Hot Stocks
DENTSPLY SIRONA received…
DENTSPLY SIRONA received written notification from The NASDAQ Stock Market on May 12, 2022 that the Company is no longer in compliance with the Nasdaq Listing Rules since the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2022. Nasdaq Listing Rule 5250(c)(1) requires Nasdaq-listed companies to timely file all periodic reports. This notice from Nasdaq has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. As previously reported by the Company in its Notification of Late Filing on Form 12b-25, filed with the Securities and Exchange Commission on May 10, 2022, the Company was unable to file the 10-Q for the period ended March 31, 2022 within the prescribed period because the Company's Audit and Finance Committee, together with independent outside counsel, is conducting an investigation concerning the Company's use of incentives to sell products to distributors in the third and fourth quarters of 2021, whether those incentives were appropriately accounted for and whether the impact of those sales was adequately disclosed in the Company's periodic reports filed with the Commission. The Company expects to file the Quarterly Report as soon as practicable.
Show Hide Related Items >> <<
05/11/22 Moderna CFO Jorge Gomez departs, recently retired David Meline to continue role 05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 05/11/22 Barrington Dentsply Sirona price target lowered to $51 from $53 at Barrington 05/10/22 Piper Sandler Piper trims Dentsply Sirona target, says recovery could be 'long and costly' 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Recommendations
Barrington analyst…
Barrington analyst Michael Petusky lowered the firm's price target on Dentsply Sirona to $51 from $53 and keeps an Outperform rating on the shares. Though he admits there is "noise" and uncertainty after the company lowered its FY22 guidance and said it now expects to generate 2-3% organic revenue growth, Petusky said he suspects that investors who purchase shares below $40 "will look very smart three years from now," though he concedes he "cannot prove it today."
Show Hide Related Items >> <<
05/11/22 Moderna CFO Jorge Gomez departs, recently retired David Meline to continue role 05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 05/10/22 Piper Sandler Piper trims Dentsply Sirona target, says recovery could be 'long and costly' 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Hot Stocks
Moderna (MRNA) announced…
Moderna (MRNA) announced that its recently appointed CFO Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr. Gomez's former employer, Dentsply Sirona (XRAY) of an ongoing internal investigation into certain matters, including financial reporting. Moderna's recently retired CFO David Meline, will continue in his role of CFO as of May 11 while Moderna reopens its search for a new CFO.
Show Hide Related Items >> <<
05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 05/04/22 Moderna sees FY22 CapEx $600M-$800M 05/04/22 Moderna reiterates its 2022 signed advance purchase agreements of $21B 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines 04/29/22 Moderna files to expand conditional vaccine authorization in EU to kids under 6 04/20/22 Piper Sandler Piper says 'do not be fooled,' Arcturus Phase 3 shows strong vaccine efficacy 04/19/22 Piper Sandler Moderna's bivalent booster improves titers against omicron, says Piper Sandler 04/11/22 Piper Sandler CFO leaves Dentsply for Moderna, outside replacement more likely, says Piper 03/25/22 Piper Sandler Moderna pipeline growing and 'de-risked,' says Piper Sandler 05/10/22 Piper Sandler Piper trims Dentsply Sirona target, says recovery could be 'long and costly' 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/04/22 Moderna reports Q1 GAAP EPS $8.58, consensus $5.21 05/03/22 Notable companies reporting before tomorrow's open 02/24/22 Moderna reports Q4 GAAP EPS $11.29, consensus $9.90 05/08/22 Moderna seeks to dismiss COVID vaccine patent lawsuit, WSJ reports 04/05/22 African Union, Covax decline more Moderna vaccines, Bloomberg says 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports 03/27/22 Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/04/22 Fly Intel: Pre-market Movers 04/18/22 Fly Insider: Sonic Automotive, Moderna among week's notable insider trades 04/05/22 What You Missed On Wall Street This Morning 03/29/22 What You Missed On Wall Street On Tuesday 12/03/21 Early notable gainers among liquid option names on December 3rd 05/09/22 Early notable gainers among liquid option names on May 9th 05/06/22 Moderna put volume heavy and directionally bearish 05/04/22 Unusually active option classes on open May 4th 05/02/22 Early notable gainers among liquid option names on May 2nd
Recommendations
Piper Sandler analyst…
Piper Sandler analyst Jason Bednar lowered the firm's price target on Dentsply Sirona to $41 from $46 and keeps a Neutral rating on the shares after the company reported Q1 revenue and EPS consistent with last month's preliminary results but reinstated guidance that shows meaningful near-term profitability pressures. In addition, the investigation from the board's audit committee into channel stuffing that may have aided in hitting comp targets is an incremental concern that adds to the risks, contends Bednar, who thinks Street estimates "may now move to a more defensible level" for 2022 and 2023. While the current valuation could provide a floor, he sees a lack of near-term catalysts and thinks the "recovery path could be long and costly," Bednar added.
Show Hide Related Items >> <<
05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 04/19/22 BofA BofA downgrades Dentsply Sirona, says 'too much unknown' after pre-announcement 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 05/10/22 Fly Intel: Pre-market Movers 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
On The Fly
Check out this morning's…
Show Hide Related Items >> <<
05/10/22 Dentsply Sirona notified SEC of late filing of 10-Q amid internal investigation 05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 05/09/22 Upstart drops 44% to $43.30 after cutting FY22 guidance 04/25/22 CFPB invokes dormant authority to examine nonbank companies 04/05/22 Upstart CEO sells $9.94M in common stock 03/10/22 Volkswagen selects Upstart Auto Retail as a preferred digital retail provider $115.98 / -21.305 (-15.52%)
03/31/22 ShockWave announces launch of peripheral intravascular lithotripsy catheter 03/30/22 ShockWave Medical announces Japanese regulatory approval of Coronary IVL 01/10/22 Penumbra says not in talks with ShockWave Medical on business combination 11/22/21 ShockWave Medical enrolls first patient in Disrupt BTK II post-market study 05/10/22 Peloton CEO: William Lynch to resign from board to pursue other interests 05/10/22 Peloton: Recent price increases 'look promising' 05/10/22 Peloton sees talent additions across organization in coming months, says CEO 05/10/22 Peloton CEO: Price increase geared towards moving hardware 05/09/22 Plug Power reaffirming 2025 targets 04/28/22 Olin, Plug Power partner to produce green hydrogen 04/27/22 Plug Power teams up with MOL Group to build green hydrogen production facility 04/19/22 Plug Power CEO: Walmart will be a key customer on our green hydrogen journey 05/06/22 Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis 05/03/22 Pfizer CEO says 'delivering on our production commitments for Paxlovid' 05/09/22 Starboard delivers open letter to LivePerson shareholders 04/08/22 LivePerson has 'constructively engaged in dialogue with Starboard' since Feb. 04/07/22 Starboard Value sends letter to LivePerson board of directors 03/01/22 LivePerson jumps after Starboard discloses stake, nominates directors 05/09/22 GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call 05/09/22 GoodRx names former Uber grocery, new verticals chief Raj Beri as COO 05/02/22 GoodRx partners with AssistRx 04/27/22 Evofem enters agreement with GoodRx's VitaCare Prescription Services 03/14/22 Clover Health appoints Joseph Martin as general counsel 02/28/22 Clover Health appoints Conrad Wai as chief technology officer 02/23/22 Clover Health says Medicare Advantage membership may grow 26%-27% in FY22 01/10/22 Clover Health reports Medicare Advantage membership growth of over 25% 03/28/22 CarGurus expands CarGurus Instant Max Cash Offer to four more states 02/22/22 CarGurus rolls out Instant Max Cash Offer to California 02/15/22 CarGurus' CarOffer reaches milestone of 10,000 enrolled dealer rooftops 12/09/21 CarGurus names Matt Quinn as Chief Technology Officer BHVN Biohaven Pharmaceutical 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash 04/29/22 Biohaven Pharmaceutical falls -14.6% 04/29/22 Biohaven Pharmaceutical falls -8.4% 04/18/22 Aterian appoints Anton von Rueden as COO 04/01/22 Aterian appoints Cynthia Williams to board of directorsHasbro 03/02/22 Aterian announces pricing of $27.5M private placement 02/01/22 Aterian appoints Susan Lattmann, Sarah Liebel to board of directors= 04/12/22 Autoliv launches multi-year commitment to support UNRSF 02/23/22 Autoliv to collaborate with Polestar on climate-neutral car 02/18/22 Autoliv provides exterior airbag for Nuro autonomous vehicle 02/17/22 Volvo committee proposes Veoneer CEO Jan Carlson as new board member BHVN Biohaven Pharmaceutical 05/02/22 Piper Sandler Piper sees 'outright misinformation' on Biohaven, says buy shares 04/22/22 Piper Sandler Biohaven widening lead over AbbVie in migraine, says Piper Sandler 03/03/22 Mizuho Biohaven Pharmaceutical price target raised to $154 from $144 at Mizuho 02/25/22 Piper Sandler Biohaven continues execution story with two deals, says Piper Sandler 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo 05/03/22 RBC Capital Clinical hold being lifted a 'clear positive' for Sangamo, says RBC Capital 04/20/22 Piper Sandler Piper says 'do not be fooled,' Arcturus Phase 3 shows strong vaccine efficacy 04/19/22 Citi Peloton assumed with Buy from Neutral at Citi 04/08/22 Morgan Stanley Peloton may top 3M Connected Fitness subscribers in Q3, says Morgan Stanley 03/31/22 Evercore ISI Peloton shares may stay range-bound in near-to-mid-term, says Evercore ISI 03/14/22 Bernstein Peloton initiated with an Outperform at Bernstein 05/10/22 Goldman Sachs Upstart downgraded to Neutral from Buy at Goldman Sachs 05/10/22 Wedbush Upstart price target lowered to $35 from $70 at Wedbush 05/10/22 Stephens Upstart downgraded to Underweight from Equal Weight at Stephens 05/10/22 Stephens Affirm downgraded to Underweight at Stephens after Upstart earnings 05/10/22 Raymond James GoodRx downgraded to Market Perform from Outperform at Raymond James 05/10/22 RBC Capital RBC Capital cuts GoodRx to Sector Perform on reduced visibility, pulled guidance 05/10/22 Barclays GoodRx price target lowered to $15 from $28 at Barclays 05/10/22 SVB Securities GoodRx downgraded to Market Perform from Outperform at SVB Leerink 03/11/22 Alliance Global Partners Aterian price target lowered to $4.50 from $9 at Alliance Global Partners 03/09/22 BTIG Aterian price target lowered to $5 from $9 at BTIG 03/09/22 DA Davidson Aterian price target lowered to $7 from $14 at DA Davidson 02/11/22 Alliance Global Partners Aterian price target lowered to $9 from $13 at Alliance Global Partners 05/10/22 Benchmark CarGurus price target lowered to $50 from $63 at Benchmark 05/10/22 BTIG CarGurus price target lowered to $43 from $49 at BTIG 05/10/22 Raymond James CarGurus price target lowered to $34 from $52 at Raymond James 05/10/22 Oppenheimer CarGurus price target lowered to $38 from $45 at Oppenheimer 05/09/22 UBS Autoliv upgraded to Buy on attractive entry point at UBS 05/09/22 UBS Autoliv upgraded to Buy from Neutral at UBS 04/26/22 Deutsche Bank Autoliv price target lowered to $86 from $96 at Deutsche Bank 04/25/22 RBC Capital Autoliv price target lowered to $97 from $116 at RBC Capital 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 04/19/22 BofA BofA downgrades Dentsply Sirona, says 'too much unknown' after pre-announcement $115.98 / -21.305 (-15.52%)
05/10/22 Canaccord ShockWave Medical price target lowered to $190 from $221 at Canaccord 05/10/22 Wells Fargo ShockWave Medical price target lowered to $176 from $235 at Wells Fargo 05/10/22 Piper Sandler ShockWave pullback an opportunity after 'strong' Q1, says Piper Sandler 04/05/22 Wolfe Research ShockWave Medical initiated with an Outperform at Wolfe Research 05/10/22 Craig-Hallum Plug Power price target lowered to $31 from $49 at Craig-Hallum 05/10/22 Susquehanna Plug Power price target lowered to $30 from $33 at Susquehanna 05/02/22 Truist Plug Power assumed with a Hold at Truist 04/26/22 KeyBanc KeyBanc says Axios report positive for Plug Power, other fuel cell names 05/10/22 B. Riley LivePerson price target lowered to $19 from $23 at B. Riley 05/10/22 Mizuho LivePerson price target lowered to $18 from $20 at Mizuho 05/10/22 Roth Capital LivePerson upgraded to Buy from Neutral at Roth Capital 04/08/22 Loop Capital LivePerson price target raised to $30 from $23 at Loop Capital 02/24/22 Canaccord Clover Health price target raised to $7 from $6 at Canaccord 02/17/22 Citi Citi opens 'negative catalyst watches' in health care services 02/02/22 Cowen Clover Health upgraded to Market Perform from Underperform at Cowen 01/19/22 SVB Securities Clover Health initiated with a Market Perform at SVB Leerink 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Upstart sees Q2 revenue $295M-$305M, consensus $334.81M 05/09/22 Upstart sees FY22 revenue $1.25B, consensus $1.4B 05/09/22 Upstart reports Q1 adjusted EPS 61c, consensus 51c 05/09/22 Notable companies reporting after market close $115.98 / -21.305 (-15.52%)
05/09/22 ShockWave Medical raises FY22 revenue view to $435M-$455M from $405-$425M 05/09/22 ShockWave Medical reports Q1 EPS 39c, consensus 18c 02/17/22 ShockWave Medical sees FY22 revenue$405M-$425M, consensus $386.73M 02/17/22 ShockWave Medical reports Q4 EPS 34c, consensus 8c 05/10/22 Peloton sees Q4 revenue $675M-$700M, consensus $821.68M 05/10/22 Peloton reports Q3 EPS ($2.27), consensus (83c) 05/09/22 Notable companies reporting before tomorrow's open 05/09/22 Plug Power reports Q1 EPS (27c), consensus (16c) 03/01/22 Plug Power reports Q4 EPS (33c), consensus (11c) 03/01/22 Notable companies reporting after market close 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/09/22 LivePerson reaffirms FY22 revenue view $544.8N-$563.3M, consensus $553.44M 05/09/22 LivePerson sees Q2 revenue $132.5M-$135.5M, consensus $135.41M 05/09/22 LivePerson reports Q1 GAAP EPS (86c), consensus (49c) 02/24/22 LivePerson sees FY22 revenue $544.8M-$563.3M, consensus $598.42M 05/09/22 GoodRx sees Q2 revenue about $190M, consensus $215.62M 05/09/22 GoodRx reports Q1 adjusted EPS 10c, consensus 8c 02/28/22 GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B 05/09/22 Clover Health reaffirms FY22 revenue view $3.0B-$3.4B, consensus $3.24B 05/09/22 Clover Health reports Q1 revenue $874.4M, consensus $787.41M 02/23/22 Clover Health sees FY22 revenue $3.0B-$3.4B, consensus $2.62B 02/23/22 Clover Health reports Q4 adjusted EBITDA ($68.5M) vs ($41.5M) last year 05/09/22 CarGurus sees Q2 adjusted EPS 26c-29c, consensus 38c 05/09/22 CarGurus reports Q1 adjusted EPS 36c, consensus 35c 02/24/22 CarGurus sees Q1 EPS 31c-33c, consensus 33c BHVN Biohaven Pharmaceutical 05/10/22 Biohaven Pharmaceutical sees 2022 net product sales $825M-$900M 05/10/22 Biohaven Pharmaceutical reports Q1 EPS ($2.97), consensus ($2.53) 02/25/22 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.32), consensus ($2.04) 05/09/22 Aterian reports Q1 EPS (78c), consensus (25c) 03/08/22 Aterian reports Q4 EPS (11c), consensus (12c) 04/22/22 Autoliv reports Q1 adjusted EPS 45c, consensus $1.11 04/22/22 Autoliv now sees FY22 organic sales growth of around 12%-17% 04/22/22 Autoliv reports Q1 adjusted EPS 45c, consensus $1.11 01/28/22 Autoliv reports Q4 adjusted EPS $1.30, consensus $1.18
Hot Stocks
Dentsply Sirona said:…
Dentsply Sirona said: "The company today has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission. As noted in the Form 12b-25, the Audit and Finance Committee of the company's Board of Directors commenced an internal investigation regarding certain financial reporting matters. The investigation is ongoing, and the company cannot predict the duration or outcome of the investigation. As a result, the company has not yet finalized its financial statements or its assessment of the impact of the investigation on its historical financial statements or for the financial statements for the three months ended March 31, 2022, and is therefore unable to file the Form 10-Q on a timely basis."
Show Hide Related Items >> <<
05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 04/19/22 Dentsply Sirona CEO Don Casey terminated, John Groetelaars named interim CEO 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 04/19/22 BofA BofA downgrades Dentsply Sirona, says 'too much unknown' after pre-announcement 05/10/22 Dentsply Sirona now sees FY22 adjusted EPS of $2.35-$2.55, consensus $2.77 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Earnings
Now sees FY22 revenue…
Now sees FY22 revenue $4.1B-$4.2B, consensus $4.23B. The company said: "Based on the results of the first quarter and a challenging macroeconomic environment, we are updating our 2022 outlook. The revised outlook for 2022 includes organic sales growth of 2% to 3%, with net sales in the range of $4.1 billion to $4.2 billion. Adjusted operating income margin is expected to be greater than 17% for the full year. Adjusted EPS is estimated to be in the range of $2.35 to $2.55."
Show Hide Related Items >> <<
05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 04/19/22 Dentsply Sirona CEO Don Casey terminated, John Groetelaars named interim CEO 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 04/19/22 BofA BofA downgrades Dentsply Sirona, says 'too much unknown' after pre-announcement 05/10/22 Dentsply Sirona reports Q1 adjusted EPS 52c, consensus 56c 05/09/22 Notable companies reporting before tomorrow's open 04/19/22 Dentsply Sirona sees Q1 adjusted EPS 48c-52c, consensus 67c 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
Earnings
Reports Q1 revenue $965M,…
Reports Q1 revenue $965M, consensus $988.43M. "The first quarter was a challenging quarter, and our financial performance and revised outlook reflect the impact of larger-than-expected macroeconomic headwinds and lower-than-expected performance in the United States. Despite these challenges, organic growth in Europe was robust, demand remains strong, and our teams are working diligently to reduce lead times to address supply chain challenges. We are confident in our ability to address these transient headwinds and we have high conviction about our future. Dental remains an attractive market. We have a healthy innovation pipeline, leading digital capabilities, and a well-positioned portfolio which will drive sustainable growth long-term," said Interim CEO John Groetelaars.
Show Hide Related Items >> <<
05/04/22 Dentsply Sirona unveils DS Core open platform 05/02/22 Dentsply Sirona changes Q1 conference call date to May 10 04/19/22 Dentsply Sirona appoints Barbara Bodem as interim CFO 04/19/22 Dentsply Sirona CEO Don Casey terminated, John Groetelaars named interim CEO 04/22/22 H.C. Wainwright Dentsply Sirona price target lowered to $48 from $58 at H.C. Wainwright 04/20/22 Barrington Dentsply Sirona price target lowered to $53 from $72 at Barrington 04/19/22 Piper Sandler Dentsply Sirona downgraded to Neutral from Overweight at Piper Sandler 04/19/22 BofA BofA downgrades Dentsply Sirona, says 'too much unknown' after pre-announcement 05/09/22 Notable companies reporting before tomorrow's open 04/19/22 Dentsply Sirona sees Q1 adjusted EPS 48c-52c, consensus 67c 02/28/22 Dentsply Sirona sees 2022 adjusted EPS $3.05-$3.25, consensus $3.19 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 01/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/03/21 Early notable gainers among liquid option names on December 3rd
